| Diabetes Mellitus
Apidra vs Fiasp
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Apidra vs Fiasp with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFiasp has a higher rate of injection site reactions vs Apidra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fiasp but not Apidra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Apidra
Fiasp
At A Glance
SC injection
With meals
Rapid-acting insulin analog
SC injection
With meals
Rapid-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus Inject SC within 15 minutes before a meal or within 20 minutes after starting a meal into the abdomen, thigh, or upper arm; generally use with an intermediate or long-acting insulin.
Continuous Subcutaneous Infusion (Insulin Pump) Administer by CSII using an insulin pump per manufacturer instructions; change reservoir at least every 48 hours; do not dilute or mix with other insulins in the pump.
Intravenous Administration Administer only under medical supervision; dilute to 0.05-1 unit/mL in 0.9% sodium chloride injection using polyvinyl chloride infusion bags.
Diabetes Mellitus - SC injection Inject at start of meal or within 20 minutes after starting a meal into abdomen, upper arm, or thigh; generally use with intermediate- or long-acting insulin; individualize dose based on metabolic needs and blood glucose monitoring.
Diabetes Mellitus - Insulin pump (CSII) Administer by continuous SC infusion using an insulin pump; change FIASP reservoir at least every 6 days or PumpCart at least every 4 days; do not mix with other insulins in the pump.
Diabetes Mellitus - IV infusion Administer only under medical supervision; dilute to 0.5-1 unit/mL in polypropylene infusion bags with 0.9% sodium chloride or 5% dextrose; stable at room temperature for 24 hours.
Contraindications
- During episodes of hypoglycemia
- Known hypersensitivity to insulin glulisine or any of the excipients in APIDRA
- Episodes of hypoglycemia
- Known hypersensitivity to insulin aspart or any excipient in FIASP
Adverse Reactions
Most common (>=5%) Nasopharyngitis, hypoglycemia, upper respiratory tract infection, influenza, peripheral edema, arthralgia, headache
Serious Severe hypoglycemia, anaphylaxis and generalized allergic reactions, hypokalemia, lipodystrophy, worsening of diabetic retinopathy, acute painful peripheral neuropathy
Postmarketing Medication errors with long-acting insulins, localized cutaneous amyloidosis, hyperglycemia and hypoglycemia associated with injection into amyloidosis sites
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, back pain (adults with T1D); urinary tract infection (adults with T2D); viral upper respiratory tract infection, upper respiratory tract infection, influenza, headache, pyrexia, vomiting (pediatric T1D)
Serious Hypoglycemia, hypokalemia, severe hypersensitivity reactions including anaphylaxis, angioedema, bronchospasm, hypotension, and shock; lipodystrophy; injection or infusion site reactions; peripheral edema; weight gain
Postmarketing Localized cutaneous amyloidosis at injection site; hyperglycemia with repeated injections into amyloidosis areas; hypoglycemia with sudden change to unaffected injection site
Pharmacology
Rapid-acting human insulin analog; lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, with more rapid onset and shorter duration of activity than regular human insulin when given subcutaneously.
Rapid-acting insulin analog; binds to insulin receptors to lower blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and inhibiting hepatic glucose output, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Apidra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Fiasp
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (9/12) · Qty limit (8/12)
UnitedHealthcare
Apidra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Fiasp
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Apidra
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Fiasp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Apidra.
No savings programs available for Fiasp.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.